VETTER-JECT
Vetter Pharma-Fertigung GmbH & Co. KG
Application Filed: 2018-09-24
Trademark Application Details
FINAL REFUSAL - MAILED
| Research |
OneLook
Acronym Finder
|
| Serial Number | 79250207 |
| Registration Number | 6791709 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | M. Scott Alprin |
| Attorney Docket Number | 0013048 |
| Law Office Assigned | N50 |
| Employee Name | SHERMAN, SAMANTHA LEIG |
Timeline
| 2018-09-24 | Application Filed |
| 2019-09-05 | Location: TMO LAW OFFICE 123 - EXAMINING ATTORNEY ASSIGNED |
| 2019-09-05 | Status: Live/Pending |
| 2019-12-06 | Transaction Date |
| 2022-07-19 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  Vetter Pharma-Fertigung GmbH & Co. KG |
| Address | Schützenstr. 87 88212 Ravensburg DE |
| Legal Entity Type | Limited Partnership |
| Legal Entity State | DE |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| International Codes: | 10 |
| U.S. Codes: | 026,039,044 |
| International Codes: | 39 |
| U.S. Codes: | 100,105 |
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations and medicines for the treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction, inflammation and inflammatory diseases, oral and laryngeal disease, optical and cranial disorders, arthritis, migraine, mucopolysaccharidosis, haemophilia, multiple sclerosis, osteoporosis, neuronal disorders, diabetes, erectile disfunction, infertility, crohn's disease, hereditary angioedema, thrombosis, encephalitis, diseases of the thyroid or parathyroid glands, metabolic diseases, muscular atrophy, disturbance of growth and anemia; pharmaceutical solutions for oral administration in the nature of pharmaceutical solutions, sterile aseptic solutions and injection solutions; sterile solutions in the nature of pharmaceutical solutions and injection solutions; injection solutions in the nature of antibody solutions, biologicals, peptides, polypeptides, proteins, enzymes, nucleic acids, coagulation factors, interferons, phosphonates and bisphosphonates, growth factors, hormones, hormone-antagonists, insulin, heparins, low molecular heparins and sulfur hexafluoride; eyedrops, contact lens solutions; medicated compresses; medical plasters, materials for dressings in the nature of bandages, wadding and gauze; filled medical injection devices, in particular syringes and instruments for injections, injectors, auto-injectors and single-chamber and dual-chamber disposable syringes, all sold filled with pharmaceutical preparations for the treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction inflammation and inflammatory diseases, oral and laryngeal disease, optical and cranial disorders, arthritis, migraine, mucopolysaccharidosis, haemophilia, multiple sclerosis, osteoporosis, neuronal disorders, diabetes, erectile disfunction, infertility, crohn's disease, hereditary angioedema, thrombosis, encephalitis, diseases of the thyroid or parathyroid glands, metabolic diseases, muscular atrophy, disturbance of growth and anemia |
| GS0391 | Bottling services, namely, bottling of liquid and solid substances, in particular of pharmaceuticals, medicines and solutions |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| SN ASSIGNED FOR SECT 66A APPL FROM IB | 2019-01-24 | 1 REPR M: |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2019-01-28 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2019-01-28 | 3 DOCK D:Assigned to Examiner |
| APPLICATION FILING RECEIPT MAILED | 2019-02-01 | 4 MAFR O:Outgoing Correspondence |
| NON-FINAL ACTION WRITTEN | 2019-02-04 | 5 CNRT R:Renewal |
| NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | 2019-02-05 | 6 RFCR E:E-Mail |
| REFUSAL PROCESSED BY MPU | 2019-02-12 | 7 RFRR P: |
| NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | 2019-02-13 | 8 RFCS P: |
| REFUSAL PROCESSED BY IB | 2019-03-02 | 9 RFNT P: |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-08-13 | 10 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-08-13 | 11 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-08-13 | 12 TEME I:Incoming Correspondence |
| FINAL REFUSAL WRITTEN | 2019-09-05 | 13 CNFR R:Renewal |
| FINAL REFUSAL E-MAILED | 2019-09-05 | 14 GNFR O:Outgoing Correspondence |
| NOTIFICATION OF FINAL REFUSAL EMAILED | 2019-09-05 | 15 GNFN O:Outgoing Correspondence |
| CORRECTION TRANSACTION RECEIVED FROM IB | 2019-11-29 | 16 CRCV M: |
| CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED | 2019-12-06 | 17 CORN I:Incoming Correspondence |
| SUSPENSION LETTER WRITTEN | 2020-03-05 | 18 CNSL R:Renewal |
| LETTER OF SUSPENSION E-MAILED | 2020-03-05 | 19 GNSL S: |
| NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | 2020-03-05 | 20 GNS3 O:Outgoing Correspondence |
| TEAS REQUEST FOR RECONSIDERATION RECEIVED | 2020-03-04 | 21 ERFR I:Incoming Correspondence |
| ASSIGNED TO LIE | 2020-03-10 | 22 ALIE A:Allowance for Publication |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2020-03-10 | 23 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2020-03-10 | 24 TEME I:Incoming Correspondence |
| SUSPENSION LETTER WRITTEN | 2020-03-12 | 25 CNSL R:Renewal |
| LETTER OF SUSPENSION E-MAILED | 2020-03-12 | 26 GNSL S: |
| NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | 2020-03-12 | 27 GNS3 O:Outgoing Correspondence |
| REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | 2020-10-02 | 28 RCSC S: |
| NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | 2021-04-28 | 29 OPNR P: |
| NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | 2021-04-28 | 30 OPNS P: |
| NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | 2021-05-16 | 31 OPNX P: |
| LIE CHECKED SUSP - TO ATTY FOR ACTION | 2021-07-28 | 32 RCCK S: |
| ACTION CONTINUING A FINAL - COMPLETED | 2021-09-27 | 33 CNCF R:Renewal |
| CONTINUATION OF FINAL REFUSAL E-MAILED | 2021-09-27 | 34 GNCF O:Outgoing Correspondence |
| NOTIFICATION OF SUBSEQUENT FINAL EMAILED | 2021-09-27 | 35 GNS1 O:Outgoing Correspondence |
| TEAS REQUEST FOR RECONSIDERATION RECEIVED | 2022-03-25 | 36 ERFR I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2022-03-25 | 37 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2022-03-26 | 38 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2022-03-27 | 39 CNSA O:Outgoing Correspondence |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2022-04-13 | 40 NONP E:E-Mail |
| NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | 2022-04-13 | 41 OP2R P: |
| NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | 2022-04-13 | 42 OPNS P: |
| PUBLISHED FOR OPPOSITION | 2022-05-03 | 43 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2022-05-03 | 44 NPUB E:E-Mail |
| NOTIFICATION PROCESSED BY IB | 2022-05-09 | 45 GPNX P: |
| REGISTERED-PRINCIPAL REGISTER | 2022-07-19 | 46 R.PR A:Allowance for Publication |
| NOTICE OF REGISTRATION CONFIRMATION EMAILED | 2022-07-19 | 47 NRCC E:E-Mail |
| FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | 2022-10-19 | 48 FICR P: |
| FINAL DISPOSITION PROCESSED | 2022-10-22 | 49 FIMP P: |
| FINAL DISPOSITION NOTICE SENT TO IB | 2022-10-22 | 50 FICS P: |
| FINAL DECISION TRANSACTION PROCESSED BY IB | 2022-11-14 | 51 FINO P: |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 